Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) have been given an average recommendation of “Buy” by the twenty-eight ratings firms that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation, twenty-six have given a buy recommendation and one has assigned a strong buy recommendation to the company. […]